New model-based analysis further supports the potential of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
September 23, 2026
September 23, 2026
NEW BRUNSWICK, New Jersey, Sept. 23 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:
* * *
New model-based analysis further supports the potential of TECVAYLI(r) (teclistamab-cqyv) plus DARZALEX FASPRO(r) (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
*
RARITAN, N.J., September 23, 2026 - Johnson & Johnson (NYSE:J . . .
* * *
New model-based analysis further supports the potential of TECVAYLI(r) (teclistamab-cqyv) plus DARZALEX FASPRO(r) (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
*
RARITAN, N.J., September 23, 2026 - Johnson & Johnson (NYSE:J . . .